相似文献
1
Illuminating the mechanism of IL-6-mediated immunotherapy resistance.
Cell Rep Med. 2023 Jan 17;4(1):100901. doi: 10.1016/j.xcrm.2022.100901.
2
CD8 cytotoxic T lymphocytes in cancer immunotherapy: A review.
J Cell Physiol. 2019 Jun;234(6):8509-8521. doi: 10.1002/jcp.27782. Epub 2018 Nov 22.
3
Enhanced anti-tumor effects of the PD-1 blockade combined with a highly absorptive form of curcumin targeting STAT3.
Cancer Sci. 2020 Dec;111(12):4326-4335. doi: 10.1111/cas.14675. Epub 2020 Oct 20.
4
Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy.
Cancer Sci. 2017 Oct;108(10):1947-1952. doi: 10.1111/cas.13332. Epub 2017 Aug 23.
5
Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment.
Theranostics. 2021 May 12;11(14):7029-7044. doi: 10.7150/thno.60040. eCollection 2021.
6
Targeting interleukin-10 signalling for cancer immunotherapy, a promising and complicated task.
Hum Vaccin Immunother. 2020 Oct 2;16(10):2328-2332. doi: 10.1080/21645515.2020.1717185. Epub 2020 Mar 11.
7
Soluble γc receptor attenuates anti-tumor responses of CD8 T cells in T cell immunotherapy.
Int J Cancer. 2018 Sep 1;143(5):1212-1223. doi: 10.1002/ijc.31402. Epub 2018 Apr 14.
8
Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Cancer Immunol Immunother. 2016 May;65(5):537-49. doi: 10.1007/s00262-016-1816-7. Epub 2016 Mar 10.
9
Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
Front Immunol. 2018 Sep 10;9:2041. doi: 10.3389/fimmu.2018.02041. eCollection 2018.
10
The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy.
Front Immunol. 2019 Jul 19;10:1574. doi: 10.3389/fimmu.2019.01574. eCollection 2019.
引用本文的文献
1
Blocking the IL‑6 pathway to treat immune checkpoint inhibitor‑induced inflammatory arthritis (Review).
Mol Med Rep. 2025 Sep;32(3). doi: 10.3892/mmr.2025.13615. Epub 2025 Jul 11.
2
Dual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study.
Cancer Immunol Immunother. 2025 Jan 3;74(2):52. doi: 10.1007/s00262-024-03899-9.
3
Tocilizumab for Advanced Non-Small-Cell Lung Cancer With Concomitant Cachexia: An Observational Study.
J Cachexia Sarcopenia Muscle. 2024 Dec;15(6):2815-2825. doi: 10.1002/jcsm.13638. Epub 2024 Nov 11.
4
SPOP downregulation promotes bladder cancer progression based on cancer cell-macrophage crosstalk via STAT3/CCL2/IL-6 axis and is regulated by VEZF1.
Theranostics. 2024 Oct 7;14(17):6543-6559. doi: 10.7150/thno.101575. eCollection 2024.
5
Combination of Anti-Angiogenics and Immunotherapies in Renal Cell Carcinoma Show Their Limits: Targeting Fibrosis to Break through the Glass Ceiling?
Biomedicines. 2024 Feb 7;12(2):385. doi: 10.3390/biomedicines12020385.
6
Gold Nanoparticles Downregulate IL-6 Expression/Production by Upregulating microRNA-26a-5p and Deactivating the RelA and NF-κBp50 Transcription Pathways in Activated Breast Cancer Cells.
Int J Mol Sci. 2024 Jan 24;25(3):1404. doi: 10.3390/ijms25031404.
7
Long Non-Coding RNA LOC339059 Attenuates IL-6/STAT3-Signaling-Mediated PDL1 Expression and Macrophage M2 Polarization by Interacting with c-Myc in Gastric Cancer.
Cancers (Basel). 2023 Nov 7;15(22):5313. doi: 10.3390/cancers15225313.
8
Endothelial Stat3 activation promotes osteoarthritis development.
Cell Prolif. 2023 Dec;56(12):e13518. doi: 10.1111/cpr.13518. Epub 2023 Jun 13.
本文引用的文献
1
CD8 T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy.
Cell Rep Med. 2023 Jan 17;4(1):100878. doi: 10.1016/j.xcrm.2022.100878. Epub 2023 Jan 3.
2
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity.
Cancer Cell. 2022 May 9;40(5):509-523.e6. doi: 10.1016/j.ccell.2022.04.004.
3
Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling.
Front Immunol. 2022 Feb 22;13:795315. doi: 10.3389/fimmu.2022.795315. eCollection 2022.
4
Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis.
Rheumatol Ther. 2020 Sep;7(3):473-516. doi: 10.1007/s40744-020-00219-2. Epub 2020 Jul 30.
5
Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition.
J Immunother Cancer. 2020 Jun;8(1). doi: 10.1136/jitc-2020-000842. Epub 2020 Jun 23.
6
Targeting the IL-6/JAK/STAT3 signalling axis in cancer.
Nat Rev Clin Oncol. 2018 Apr;15(4):234-248. doi: 10.1038/nrclinonc.2018.8. Epub 2018 Feb 6.
7
Revisiting STAT3 signalling in cancer: new and unexpected biological functions.
Nat Rev Cancer. 2014 Nov;14(11):736-46. doi: 10.1038/nrc3818.
8
IL-6 in inflammation, immunity, and disease.
Cold Spring Harb Perspect Biol. 2014 Sep 4;6(10):a016295. doi: 10.1101/cshperspect.a016295.
Zotero 插件